PV-INFOLINK
27.5.2019 09:02:04 CEST | Business Wire | Press release
Upon the return of SNEC PV Power Expo next month, PV InfoLink will explore the PV product trends and the transition of module output at a seminar held in Shanghai on June 3.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005064/en/
Titled “2H19 PV Market Outlook and Forecast,” the seminar will feature topics spanning China’s transition to subsidy-free market , PV market outlook and supply chain. PV InfoLink, a leading solar market research firm and host of the seminar, has invited top-tier companies including Jinko, Longi, and GCL-Si to discuss the major issues.
As the global PV market grows continuously, China’s module exports had hit a record high of 16 GW in Q1’19, a significant growth from last Q4’s 12 GW. In addition to India and Japan’s traditional high season, China exported 5 GW of modules to the European markets in Q1.
Following the release of Chinese PV policies, market demand is expected to heat up in July. Thus, PV InfoLink projected that the global demand this year will amount to 123 GW, a 25% growth from last year.
SE-PERC modules have become a norm for high-efficiency, however, it’s getting more difficult to make new breakthrough on cell side, therefore, it requires module technologies and larger wafers to achieve higher module power output. According to China customs data, total exports of special solar modules paired with module technologies had exceeded 2GW in Q1, surpassing the cumulative volume of special modules last year.
So far, special modules accounted for 17% of total Chinese module exports. Among them, half-cut module is by far the most mature technology. Australia, the Netherlands, and Japan are the top trading partners of China in terms of half-cut modules, having imported mostly 60-cell 315-320W and 72-cell 370-375W modules.
Shingled modules have higher output than others. However, exporting shingled modules is rather restricted due to patent protection. So far, China exported only 253 MW of 60-cell 320-330W and 72-cell 395-400W modules to Australia and Asian countries in Q1.
This year also saw the emergence of panels consisting of more cells, which can push up 78-cell modules’ output to 400 W.
Overall, the module output has improved significantly this year. 60-cell P-type module output can achieve 315W-320W through using larger wafers or half-cut cells. After the use of larger wafers becomes more common in the second half, some of the P-type modules could achieve 325-330W of output, and that will put N-type modules under pressure because of its lower cost-performance.
Vikram Solar, a Tier 1 solar module manufacturer and EPC solutions provider that has played an important role in shaping PV revolution, is a golden sponsor of the event.
PV InfoLink provides the most up-to-date market information and accurate price quotes across the supply chain, which is referenced by most large companies for price negotiation to stay competitive in the market. Details on how to attend the seminar can be found through the event page here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005064/en/
Contact:
PV InfoLink Ellie Lee service@pvinfolink.com +886 227163123
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
